These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7067171)

  • 1. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H; Alvestrand A; Fürst P; Bergström J
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation and excretion of middle molecules.
    Asaba H
    Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P; Zimmerman L; Bergström J
    Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
    Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
    Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cytotoxic properties of plasma samples from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of middle molecular weight fraction in the plasma of patients with uremia using high performance liquid chromatography and thin layer chromatography].
    Kovalishin IaF; Nikolaev VG; Baran EIa; Dudar' IA; Iushko LA
    Vopr Med Khim; 1988; 34(6):23-6. PubMed ID: 3238937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
    Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
    J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodology for identification of serum middle molecules.
    Buzio C; Montagna G; Calderini C; Manari A; Migone L
    Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 19. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
    Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV
    Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.